Phio Pharmaceuticals (NASDAQ:PHIO) vs. F-star Therapeutics (NASDAQ:FSTX) Head to Head Review

Phio Pharmaceuticals (NASDAQ:PHIOGet Rating) and F-star Therapeutics (NASDAQ:FSTXGet Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings.

Earnings and Valuation

This table compares Phio Pharmaceuticals and F-star Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Phio Pharmaceuticals $20,000.00 457.58 -$13.29 million ($0.92) -0.73
F-star Therapeutics $21.17 million 3.47 -$31.28 million ($1.54) -2.21

Phio Pharmaceuticals has higher earnings, but lower revenue than F-star Therapeutics. F-star Therapeutics is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Phio Pharmaceuticals and F-star Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Phio Pharmaceuticals 0 0 1 0 3.00
F-star Therapeutics 0 0 5 0 3.00

Phio Pharmaceuticals presently has a consensus target price of $6.00, suggesting a potential upside of 795.52%. F-star Therapeutics has a consensus target price of $29.50, suggesting a potential upside of 765.10%. Given Phio Pharmaceuticals’ higher possible upside, equities analysts plainly believe Phio Pharmaceuticals is more favorable than F-star Therapeutics.

Profitability

This table compares Phio Pharmaceuticals and F-star Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Phio Pharmaceuticals N/A -52.04% -46.47%
F-star Therapeutics N/A -36.13% -28.30%

Institutional & Insider Ownership

13.2% of Phio Pharmaceuticals shares are held by institutional investors. Comparatively, 51.7% of F-star Therapeutics shares are held by institutional investors. 0.3% of Phio Pharmaceuticals shares are held by insiders. Comparatively, 3.2% of F-star Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Phio Pharmaceuticals has a beta of 1.69, indicating that its stock price is 69% more volatile than the S&P 500. Comparatively, F-star Therapeutics has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500.

Summary

F-star Therapeutics beats Phio Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About Phio Pharmaceuticals (Get Rating)

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

About F-star Therapeutics (Get Rating)

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.

Want More Great Investing Ideas?

Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.